Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do

SIMPLE SUMMARY: Immune checkpoint inhibitors, including monoclonal antibodies directed against the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway or the cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway and the most recent lymphocyte-activation gene 3 (LAG-3)—blocking...

Descripción completa

Detalles Bibliográficos
Autores principales: Zito, Concetta, Manganaro, Roberta, Ciappina, Giuliana, Spagnolo, Calogera Claudia, Racanelli, Vito, Santarpia, Mariacarmela, Silvestris, Nicola, Carerj, Scipione
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653561/
https://www.ncbi.nlm.nih.gov/pubmed/36358830
http://dx.doi.org/10.3390/cancers14215403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653561/
https://www.ncbi.nlm.nih.gov/pubmed/36358830
http://dx.doi.org/10.3390/cancers14215403

Ejemplares similares